PURPOSE: Waldenstrom's macroglobulinemia (WM) is a B-cell disorder. Despite advances in the therapy, WM remains incurable. As such, novel therapeutic agents are needed for the treatment of WM. EXPERIMENTAL DESIGN: In this multicenter study, 27 patients with WM received up to eight cycles of bortezomib at 1.3 mg/m(2) on days 1, 4, 8, and 11. All but one patient had relapsed/or refractory disease. RESULTS: Following therapy, median serum IgM levels declined from 4,660 to 2,092 mg/dL (P < 0.0001). The overall response rate was 85%, with 10 and 13 patients achieving minor and major responses, respectively. Responses were prompt and occurred at median of 1.4 months. The median time to progression for all responding patients was 7.9 (range, 3-21.4+) months. The most common grade III/IV toxicities occurring in > or =5% of patients were sensory neuropathies (22.2%), leukopenia (18.5%), neutropenia (14.8%), dizziness (11.1%), and thrombocytopenia (7.4%). Sensory neuropathies resolved or improved in nearly all patients following cessation of therapy. CONCLUSIONS: The results of these studies show that bortezomib is an active agent in relapsed and refractory WM.
PURPOSE:Waldenstrom's macroglobulinemia (WM) is a B-cell disorder. Despite advances in the therapy, WM remains incurable. As such, novel therapeutic agents are needed for the treatment of WM. EXPERIMENTAL DESIGN: In this multicenter study, 27 patients with WM received up to eight cycles of bortezomib at 1.3 mg/m(2) on days 1, 4, 8, and 11. All but one patient had relapsed/or refractory disease. RESULTS: Following therapy, median serum IgM levels declined from 4,660 to 2,092 mg/dL (P < 0.0001). The overall response rate was 85%, with 10 and 13 patients achieving minor and major responses, respectively. Responses were prompt and occurred at median of 1.4 months. The median time to progression for all responding patients was 7.9 (range, 3-21.4+) months. The most common grade III/IV toxicities occurring in > or =5% of patients were sensory neuropathies (22.2%), leukopenia (18.5%), neutropenia (14.8%), dizziness (11.1%), and thrombocytopenia (7.4%). Sensory neuropathies resolved or improved in nearly all patients following cessation of therapy. CONCLUSIONS: The results of these studies show that bortezomib is an active agent in relapsed and refractory WM.
Authors: Meletios A Dimopoulos; Efstathios Kastritis; Roger G Owen; Robert A Kyle; Ola Landgren; Enrica Morra; Xavier Leleu; Ramón García-Sanz; Nikhil Munshi; Kenneth C Anderson; Evangelos Terpos; Irene M Ghobrial; Pierre Morel; David Maloney; Mathias Rummel; Véronique Leblond; Ranjana H Advani; Morie A Gertz; Charalampia Kyriakou; Sheeba K Thomas; Bart Barlogie; Stephanie A Gregory; Eva Kimby; Giampaolo Merlini; Steven P Treon Journal: Blood Date: 2014-07-15 Impact factor: 22.113
Authors: Sigurdur Y Kristinsson; Sandra Eloranta; Paul W Dickman; Therese M-L Andersson; Ingemar Turesson; Ola Landgren; Magnus Björkholm Journal: Am J Hematol Date: 2012-11-19 Impact factor: 10.047
Authors: L Xu; Z R Hunter; G Yang; Y Cao; X Liu; R Manning; C Tripsas; J Chen; C J Patterson; M Kluk; S Kanan; J Castillo; N Lindeman; S P Treon Journal: Leukemia Date: 2014-02-10 Impact factor: 11.528
Authors: Isere Kuiatse; Veerabhadran Baladandayuthapani; Heather Y Lin; Sheeba K Thomas; Chad C Bjorklund; Donna M Weber; Michael Wang; Jatin J Shah; Xing-Ding Zhang; Richard J Jones; Stephen M Ansell; Guang Yang; Steven P Treon; Robert Z Orlowski Journal: Clin Cancer Res Date: 2015-03-06 Impact factor: 12.531
Authors: Esteban Braggio; Jonathan J Keats; Xavier Leleu; Scott Van Wier; Victor H Jimenez-Zepeda; Riccardo Valdez; Roelandt F J Schop; Tammy Price-Troska; Kimberly Henderson; Antonio Sacco; Feda Azab; Philip Greipp; Morie Gertz; Suzanne Hayman; S Vincent Rajkumar; John Carpten; Marta Chesi; Michael Barrett; A Keith Stewart; Ahmet Dogan; P Leif Bergsagel; Irene M Ghobrial; Rafael Fonseca Journal: Cancer Res Date: 2009-04-07 Impact factor: 12.701